Insulin Potentiation Therapy (IPT) is a safe and innovative approach to treating cancer. The key to IPT lies in the use of insulin. Insulin Potentiation Therapy uses a combination of insulin and low-dose chemotherapy; cancer cells have highly active insulin receptors, and IPT takes advantage of this characteristic. Also, IPT has almost none of the side effects – nausea, radical hair loss, liver damage, and DNA distortion – with standard chemotherapy.
Metronomic chemotherapy exerts its anti-cancer activity mainly by inhibiting tumor growth. Low doses of chemotherapeutic drugs administered frequently (“metronomic” dosing) can affect tumor tissue and inhibit tumor growth. This metronomic approach inhibits the growth of tumor-initiating cells (TICs) in the blood vessels of the tumor. Metronomic Therapy hits cancer at the source while also suppressing the growth of resistant cells.
Conceived in the early 1970s, anti-angiogenic therapy is based on the idea that by cutting the blood supply off, cancer cells can be deprived of nutrients and treated. Recent advances in knowledge on various anti-angiogenic agents, identification of potential targets, and understanding on the molecular mechanisms by which these agents elicit their responses have made it possible to use anti-angiogenic therapy as a practical treatment of many cancers.
Viral Immune Therapy
There are three types of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene treatment and viral immunotherapy. At its core, viral immune therapy boosts the immune system and selectively kills cancer cells without harming healthy cells. Basically, a doctor injects a virus into the tumor, and then the virus enters the cancer cells. As the cells die, they release antigens to trigger the patient’s immune system to target the cancer cells with the same antigens.